Almotriptan Patent to Expire in May 2015

Almotriptan Patent to Expire in May 2015

almotriptanKnown as the brand name migraine treatment Axert, marketed by Ortho-McNeil Pharmaceuticals, Almotriptan’s patent protection expires in May 2015. This is exciting news for research and development teams who are currently seeking to provide migraine sufferers with additional therapies. Almotriptan, or Axert, is currently FDA approved to treat migraine with or without aura in adults and adolescents ages 12 to 17. Clinical trials and post marketing reports have shown encouraging results from patients of all ages, with few adverse effects noted. Common side effects reported include slight nausea, dry mouth and a tired feeling.

The publication Headache: The Journal of Head and Face Pain revealed overwhelming support for the use of various triptans for migraine patients if current therapies were inadequate. Clinical data from a swath of patients that previously found Sumatriptan (Imitrex) to be ineffective were instead administered Almotriptan at the onset of their next migraine. A sizable 47 percent of these patients who received Almotriptan experienced total pain relief two hours post dosage. Researchers have come to understand that not all migraine patients are the same, and not all triptans are equal either. As an efficacious serotonin (5HT) inhibitor triptan, Almotriptan has become a viable option for patients who find a lack of efficacy or devastating side effects occur from other triptan therapies.

According to the Migraine Research Foundation one in four U.S. households has a person who suffers from migraines. Roughly 18 percent of women and 6 percent of men are afflicted with migraine headaches as well. Additionally, migraine headaches rank in the top 20 of the most disabling medical illnesses worldwide. Continued R&D is needed to combat the great need for innovative therapies to treat this growing patient population. LGM Pharma can assist clients as a supplier/distributor of the API Almotriptan, CAS # 154323-57-6, for research and development purposes. Clients can be assured of quality API products and continuous support throughout the R&D process.

Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e) +A13(1). Any patent infringement and resulting liability is solely at buyer risk.

  • Share:

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service